Pre-Open Stock Movers 03/30: (ACAD) (VICL) (ANTM) Higher; (CTRV) (VRNT) (LNDC) Lower (more...)

March 30, 2016 9:36 AM EDT
Get Alerts CTRV Hot Sheet
Price: $3.58 --0%

Overall Analyst Rating:
    NEUTRAL (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) 23.4% LOWER; announced the pricing of a best efforts underwritten public offering of up to 4,929,578 shares of its common stock and warrants to purchase up to 2,464,789 shares of the Company's common stock at a fixed combined price to the public of $1.42.

Acadia Pharma (NASDAQ: ACAD) 19.5% HIGHER; FDA panel backing for NUPLAZID.

Vical Incorporated (Nasdaq: VICL) 17.1% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Vical Fast Track designation for its investigational antifungal product candidate, VL-2397, for the treatment of invasive aspergillosis. The FDA’s Fast Track program is designed to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need.

Verint Systems (NASDAQ: VRNT) 14.1% LOWER; reported Q4 EPS of $0.90, $0.27 worse than the analyst estimate of $1.17. Revenue for the quarter came in at $280.8 million versus the consensus estimate of $318.04 million. Also, announced that Verint’s board of directors has authorized the Company to repurchase up to $150 million of common stock over the next two years. Downgraded at Credit Suisse.

Landec (NASDAQ: LNDC) 12.6% LOWER; reported Q3 EPS of $0.01, $0.02 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $130 million versus the consensus estimate of $136.99 million. GUIDANCE: Landec sees FY2016 EPS of $0.33-$0.37, versus the consensus of $0.39.

Actinium Pharma's (NYSE: ATNM) 9.4% HIGHER; 131I-BC8 monoclonal antibody was granted orphan status for treatment of Acute AML.

OPKO Health, Inc. (NYSE: OPK) 9.4% LOWER; announces that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the Companys New Drug Application (NDA) for RAYALDEE® (calcifediol) as a treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

DeVry Education Group (NYSE: DV) 9% LOWER; 4.8 million share block trade offer. According to Bloomberg, citing a person familiar, the trade was offered via Citigroup at $17.05-$17.55.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) 7% HIGHER; announced pre-clinical data demonstrating significant anti-fibrotic activity of Aramchol in methionine and choline deficient (MCD) diet in mice.

Sonic Corp (NASDAQ: SONC) 6.2% HIGHER; reported Q2 EPS of $0.18, $0.02 better than the analyst estimate of $0.16. Revenue for the quarter came in at $133.2 million versus the consensus estimate of $127.73 million.

lululemon athletica (NASDAQ: LULU) 5.9% HIGHER; reported Q4 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $704.3 million versus the consensus estimate of $693.38 million.

Westport (NASDAQ: WPRT) 5.2% LOWER; reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $25.1 million versus the consensus estimate of $32.36 million.

Valeant Pharmaceuticals (NYSE: VRX) 4.5% HIGHER; announced that, as anticipated and consistent with its previously disclosed intention, it has launched the process to obtain an amendment and waiver to its credit facility.

Sage Therapeutics (NASDAQ: SAGE) 4.5% HIGHER; Goldman Sachs initiated coverage with a Buy rating.

Shake Shack (NYSE: SHAK) 4.2% HIGHER; Longbow Research upgraded from Neutral to Buy with a price target of $46.00.

Rio Tinto (NYSE: RIO) 3.5% HIGHER; Argus initiates coverage with a Buy rating and a price target of $36.00.

Vince Holding (NYSE: VNCE) 3.1% LOWER; reported Q4 EPS of $0.01, $0.01 better than the analyst estimate of $0.00. Revenue for the quarter came in at $81.8 million versus the consensus estimate of $81.05 million. Vince Holding reaffirmed FY2016 guidance.

STORE Capital Corporation (NYSE: STOR) 2.1% LOWER; announced the pricing of its previously announced secondary public offering. Pursuant to the offering, STORE Holding Company, LLC (“STORE Holding”), a stockholder affiliated with Oaktree Capital Management, L.P., is selling all 33,336,144 shares of STORE Capital’s common stock it owns. The public offering price is $25.25 per share, and the offering is expected to close on or about April 1, 2016, subject to customary closing conditions. Immediately following the offering, STORE Holding will not own any shares of STORE Capital common stock.

Dave & Buster's Entertainment (NASDAQ: PLAY) 1.4% LOWER; reported Q4 EPS of $0.53, $0.10 better than the analyst estimate of $0.43. Revenue for the quarter came in at $234.2 million versus the consensus estimate of $229.36 million. Dave & Buster's Entertainment sees FY2016 revenue of $967-987 million, versus the consensus of $975.97 million.

Restoration Hardware (NYSE: RH) 1.4% LOWER; reported Q4 EPS of $0.98, versus $1.02 reported last year. Revenue for the quarter came in at $647.2 million, versus $582.7 million reported last year. Comparable brand revenue growth, which includes direct, was 11% in fiscal 2015 on top of 20% for the same period last year. GUIDANCE: Restoration Hardware sees Q1 2016 EPS of $0.04-$0.06. Restoration Hardware sees Q1 2016 revenue of $452-456 million.

Apple (NASDAQ: AAPL) 1.3% HIGHER; Cowen upgrades from Market Perform to Outperform with a price target of $135.00 (prior $125.00).

Agios Pharma (NASDAQ: AGIO) 1% HIGHER; SunTrust Robinson Humphrey initiated coverage with a Buy rating and a price target of $57.00.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Credit Suisse, Goldman Sachs, Citi, SunTrust Robinson Humphrey, Longbow Research, Argus, Cowen & Co, Pre-Open Losers, Pre-Open Winners, Pre Market Movers